Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Phase 2 Terminated 13 enrolled Peter Kozuch Genentech, Inc. · collab Hoffmann-La Roche · collab

NaSingle-groupOpen-labelTreatment

Summary

To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer. Time to tumor progression, objective response rate, time to confirmed response rate, duration of confirmed response rate, time to treatment failure, and CEA response will be assessed.

Timeline

Start: 2004-06
Primary completion: 2005-06
Completion: 2005-06

Outcome

Outcome not reported

Stopped: “Study halted by drug manufacturer”

Publications

Background Van Halteren HK, Roumen RM, Coebergh JW, Croiset van Uchelen FA, Keuning JJ, Vreugdenhil G. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer. Anticancer Res. 1999 Jul-Aug;19(4C):3447-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	—	Oral
Subject	Erlotinib	Small molecule	—	Oral